on 25 Aug 2020
Last Applicant/ Owned by
55131 Mainz
DE
Serial Number
79267601 filed on 01st Jul 2019
Registration Number
6132512 registered on 25th Aug 2020
Correspondent Address
Catherine C. Miller
Filing Basis
No Filing Basis
Disclaimer
NO DATA
Scientific apparatuses and instruments, namely, next generation sequencers for laboratory research use; software algorithms, namely, downloadable software programs for use in analyzing next generation sequencer data, in particular for the detection and collection of mutations in cancer patients Pharmaceutical products for the treatment of cancer, in particular based on nucleic acids and/or proteiRead More
Pharmaceutical products for the treatment of cancer, in particular based on nucleic acids and/or proteins; personalised patient-specific medicinal products, in particular based on nucleic acids and/or proteins, namely, pharmaceutical preparations for treatment of cancer diseases, autoimmune diseases, and infectious diseases
Scientific apparatuses and instruments, namely, next generation sequencers for laboratory research use; software algorithms, namely, downloadable software programs for use in analyzing next generation sequencer data, in particular for the detection and collection of mutations in cancer patients
High-throughput analytical instruments, in particular instruments for next-generation sequencing (NGS) for medical issues, as well as for gene expression profiling and for the detection of epigenetic changes, namely, high throughput genome and exome gene sequencers for medical use
Medical research and development in the field of cancer immunotherapy, in particular research and development in the field of human and veterinary medical diagnostics and treatment by means of molecular-biological, genetic, biotechnological and/or bioinformatic methods, in particular by means of next-generation sequencing; Scientific laboratory services and scientific research services featuring diagnostics of tumour markers for personalised treatment
Medical, veterinary-medical and pharmaceutical advisory services, in particular in the selection of suitable treatments for cancer diseases of all kinds; Medical services, namely, performance of analyses and treatments as part of personalised cancer immunotherapy; Medical services for the treatment of cancer, namely, provision of treatments based on nucleic acids and/or checkpoint inhibitors
No 79267601
No Service Mark
No 108166.0003
No
No
No
No
No
No
No
No
| Status Date | Action Taken |
|---|---|
| 15th Apr 2022 | NEW REPRESENTATIVE AT IB RECEIVED |
| 19th Dec 2020 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| 02th Dec 2020 | FINAL DISPOSITION NOTICE SENT TO IB |
| 01st Dec 2020 | FINAL DISPOSITION PROCESSED |
| 25th Nov 2020 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| 25th Aug 2020 | REGISTERED-PRINCIPAL REGISTER |
| 09th Jun 2020 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 09th Jun 2020 | PUBLISHED FOR OPPOSITION |
| 05th Jun 2020 | NOTIFICATION PROCESSED BY IB |
| 20th May 2020 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
